DAX ®12.847,68+3,36%TecDAX ®3.250,99+0,13%S&P FUTURE3.176,40+0,46%Nasdaq 100 Future9.808,50+1,89%
finanztreff.de

DGAP-Adhoc: Xlife Sciences AG: Active pharmaceutical ingredient for pneumonia caused by COVID-19 (coronavirus)

| Quelle: Dow Jones Newsw... | Lesedauer etwa 2 min. | Text vorlesen Stop Pause Fortsetzen


DGAP-Ad-hoc: Xlife Sciences AG / Key word(s): Miscellaneous
Xlife Sciences AG: Active pharmaceutical ingredient for pneumonia caused by
COVID-19 (coronavirus)

11-March-2020 / 08:01 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

*Xlife Sciences AG: Active pharmaceutical ingredient for pneumonia caused by
COVID-19 (coronavirus)*

Xlife Sciences AG tests a new therapy for the treatment of pneumonia caused
by coronavirus in cooperation with the Institute of Virology and Immunology
(IVI) of the Vetsuisse Faculty of the University of Bern in Switzerland.
Advantages of the therapy are a fundamentally better biovariability and a
broad target diversity. The necessary documents have successfully been
submitted.

*About Xlife Sciences AG*

Xlife Sciences AG (m:access: XLS) is a Swiss company with focus on investing
in promising technologies in the life science industry. Xlife Sciences AG is
buildingthe bridge from research and development to healthcare markets.
Together with industrial partners or universities, Xlife Sciences AG leads
projects through the proof-of-concept phase after an invention disclosure or
start-up. Subsequently, the firm focuses on out-licensing or selling the
company, often with a combination of a strategic partnership. Xlife Sciences
AG offers its investors direct access to the further development of
innovative and future-oriented technologies at a very early stage.
For more information, please visit: www.xlifesciences.ch [1]

11-March-2020 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Xlife Sciences AG
Klausstrasse 19
8008 Zürich
Switzerland
Phone: 0041 44 385 84 60
E-mail: info@xlifesciences.ch
Internet: www.xlifesciences.ch
ISIN: CH0461929603
WKN: A2PK6Z
Listed: Regulated Unofficial Market in Munich
EQS News ID: 993771

End of Announcement DGAP News Service

993771 11-March-2020 CET/CEST


1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=90cbe54b2705cc78ac2cc5fee6b5091f&application_id=993771&site_id=vwd&application_name=news


(END) Dow Jones Newswires

March 11, 2020 03:01 ET ( 07:01 GMT)
Werbung

Das könnte Sie auch interessieren

News-Suche

Suchbegriff:

Aktuelle Videos

HSBC Trading TV

Werbung

Trading-Tipp

Börsen & Märkte

US-Marktüberblick

zur Mediathek
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 24 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen